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Porcine  reproductive  and  respiratory  syndrome  virus  (PRRSV)  is prevalent  in  swine  farms  worldwide  and
is  a major  source  of  economic  loss  and  animal  suffering.  Rapid  genetic  variation  of  PRRSV  makes  it difﬁcult
for  current  vaccines  to confer  protection  against  newly  emerging  strains.  We  recently  demonstrated
that  a  novel  peptide  nanoﬁber  hydrogel  (H9e)  could  act  as  a  potent  adjuvant  for  killed H1N1  vaccines.
Therefore,  the  objective  of this  study  was  to evaluate  H9e  as an  adjuvant  for  PRRSV  modiﬁed  live virus
(MLV)  vaccines.  Pigs  were  vaccinated  with  Ingelvac  PRRSV  MLV  with  or  without  H9e  adjuvant  before
being  challenged  with  the  VR-2332  (parental  vaccine  strain)  or MN184A  (genetically  diverse  strain)
PRRSV.  Pigs  vaccinated  with  MLV  +  H9e  had  higher  levels  of  circulating  vaccine  virus.  More  importantly,
pigs  vaccinated  with  MLV  + H9e  had  improved  protection  against  challenge  by both  PRRSV  strains,  asRRSV demonstrated  by reduced  challenge-induced  viremia  compared  with  pigs  vaccinated  with MLV  alone.
Pigs  vaccinated  with  MLV  + H9e  had  lower  frequency  of  T-regulatory  cells  and  IL-10  production  but  higher
frequency  of  Th/memory  cells and  IFN-  secretion  than  that  in  pigs  vaccinated  with  MLV  alone.  Taken
together,  our  studies  suggest  that  the  peptide  nanoﬁber  hydrogel  H9e,  when  combined  with the  PRRSV
MLV  vaccine,  can  enhance  vaccine  efﬁcacy  against  two  different  PRRSV  strains  by  modulating  both  host
humoral  and  cellular  immune  responses.
2013©
. Introduction
Pork is one of the most widely consumed meats in the world,
ccounting for more than a third of meat production worldwide.
nfectious diseases remain the biggest threat to the pork industry,
esulting in billions of dollars in economic losses [1]. One particu-
arly devastating disease known to lead to the dramatic decline of
wine herds and increased pork prices is porcine reproductive and
espiratory syndrome (PRRS) [1]. Clinical features of PRRS include
assive abortion in sows and weight loss, respiratory disease,
nd mortality in young pigs. PRRS outbreaks continue to emerge
apidly and with increased virulence; if left untreated, outbreaks
ill endanger swine industries worldwide.
PRRS is caused by the PRRS virus (PRRSV). Field isolates often
iffer signiﬁcantly in the degree of virulence and pathogenicity,
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presumably due to a high degree of genetic variation among strains
[2]. PRRSV can be broadly divided into two distinct genotypes, Type
1 (European) and Type 2 (North American). Each genotype also con-
tains several subtypes, which are also genetically diverse and lead
to immunity limited to the initial infecting genotype, with only
partial or no protection from reinfection by other subtypes [3]. Due
to genetic diversity and the rapid evolution rate of PRRSV, devel-
opment of a broadly protective PRRSV vaccine is challenging, but
vaccination remains the most effective way to control PRRS. Sev-
eral types of commercial vaccines, including killed or modiﬁed live
vaccines, have been widely used [4]. Current killed vaccines are
largely ineffective in preventing both PRRSV infection and disease,
so most farms vaccinate their herds with modiﬁed live vaccines to
control PRRS outbreaks. Modiﬁed live vaccines are shown to reduce
disease caused by genetically similar strains, but they provide very
limited or no protection against genetically unrelated ﬁeld isolates
[5]. Therefore, broad cross-protection against genetically dissimilar
PRRSV strains should be the main consideration for the design of
Open access under CC BY-NC-ND license.improved PRRSV vaccines.
Adjuvants  including oil-in-water emulsions, polymers, and bac-
terial antigens have been tested in combination with modiﬁed live
vaccines in an effort to reduce the antigenic load and improve
 license.
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accine efﬁcacy [6,7]. Results from these studies suggest that addi-
ion of adjuvant to MLV  PRRSV vaccines can lead to increased
rotection to PRRSV challenge. Peptide hydrogels also might be
 promising delivery system for vaccines due to their high water
ontent, polymer network and reversible sol–gel (solution to gel)
ormation. Peptide hydrogels have been well studied as drug deliv-
ry systems, for tissue engineering applications, and in 3-D cell
ulture and show promising results [8,9]. We  recently developed a
ovel peptide that can form a ﬂexible nanoﬁber hydrogel (H9e) and
unctions as a potent adjuvant for killed H1N1 inﬂuenza vaccines
10]. To further characterize the capabilities of the H9e hydrogel,
e evaluated H9e as an adjuvant for PRRSV MLV  vaccines. Results
how that the addition of H9e to MLV  enhanced protection of
igs to both homologous and heterologous strains of PRRSV. Com-
ared with pigs vaccinated with MLV  alone, animals vaccinated
ith MLV  + H9e developed earlier and more robust PRRSV-speciﬁc
eutralizing antibodies as well as increased PRRSV-speciﬁc Th1
ytokine IFN- and reduced immunosuppressive cytokine IL-10.
ogether, these results suggest that PRRS MLV  vaccine formulated
ith H9e adjuvant may  increase vaccine efﬁcacy against genetically
iverse PRRS viruses.
.  Materials and methods
.1.  Cells, virus and adjuvant preparation
MARC-145 cells were maintained in modiﬁed Eagle’s medium
MEM) supplemented with 7% fetal bovine serum (FBS) contain-
ng penicillin (100 U/ml) and streptomycin (100 g/ml) at 37 ◦C
ith 5% CO2. For virus infection and titration, MEM  supplemented
ith 2% FBS was used. Ingelvac PRRS® modiﬁed live virus vaccine
MLV) was purchased from Boehringer Ingelheim Vetmedica Inc.
St. Joseph, MO). PRRSV MN184A was a kind gift from Dr. Kay
aaberg (National Animal Disease Center, USDA-ARS, Ames, IA).
RRSV strains VR-2332 (ATCC, Manassas, VA) and MN184A were
repared and titered in MARC-145 cells and stored in aliquots
t −80 ◦C until use. H9e peptide was prepared as previously
escribed with a ﬁnal concentration of 17.5 mg/ml  [10]. PRRS MLV
accine was resuspended in 50 ml  vaccine diluent, provided by
he manufacturer, to yield a 2-fold concentrate of vaccine virus.
LV-alone vaccine was  then mixed 1:1 with vaccine diluent. A
olution of 6 mg  H9e with 1.2% porcine serum in diluent/MEM
edium was added 1:1 with 2× MLV  to prepare MLV  + H9e
accine.
.2. Pigs, vaccination and PRRSV challenge
Thirty-ﬁve female/unvaccinated (3 weeks old) Large White-
uroc crossbred PRRSV-free pigs were divided into 7 groups (n = 5)
nd housed in separate pens within the Large Animal Research Cen-
er (LARC) at Kansas State University. These piglets were conﬁrmed
era-negative for antibodies to PRRSV by ELISA and PRRSV-free
n serum by RT-PCR. Pigs were immunized intramuscularly on
ay 0 with placebo, PRRS-MLV (1 × 106 TCID50/pig), or PRRS-
LV + H9e (1 × 106 TCID50 + 6 mg  H9e/pig). Twenty-eight days post
accination (DPV), the pigs were challenged with either homol-
gous PRRSV VR-2332 (1 × 106 TCID50) or heterologous MN184A
5 × 105 TCID50). Body weight measurements and blood samples
ere collected weekly (0, 7, 14, 21, 28 DPV and 7, 14 DPC).
igs were also monitored daily for rectal temperature and clinical
igns after challenge. All pigs were humanly euthanized 15 days
ost challenge (DPC). All animal experiments were approved by
he Institutional Animal Care and Use Committee at Kansas State
niversity.013) 4508– 4515 4509
2.3. Analysis of serum virus titer
Total RNA was extracted from serum and one-step SyBR Green
real-time PCR (Bio-Rad, Hercules, CA) was performed to evalu-
ate the PRRSV ORF7 expression level as previously described [11].
For quantiﬁcation, total RNA of a known TCID50 of virus was  10-
fold serially diluted and were used to generate a standard curve.
The virus quantities of unknown samples were determined by
linear extrapolation of the Ct value plotted against the standard
curve.
2.4. PRRSV-speciﬁc and virus neutralizing antibody titration
PRRSV-speciﬁc ELISA antibody titers were measured using the
Herdcheck Porcine Reproductive and Respiratory Syndrome X3
Antibody Test (IDEXX Laboratories, Westbrook, ME)  as described
by the manufacturer. Virus neutralizing antibody titer in the serum
was analyzed as previously described [11]. Brieﬂy, serum samples
were heat-inactivated and serial dilutions were mixed with PRRSV
VR-2332 or MN184A viruses. After incubation, the mixtures were
transferred to MARC-145 cells and incubated for 72 h. Cytopathic
effect (CPE) was  used to determine the end-point titers that were
calculated as the reciprocal of the highest serum dilution to neu-
tralize >90% CPE induced by 200 TCID50 of PRRSV in duplicate wells
per sample.
2.5. Analysis of cytokine responses
Pig sera were collected at 7 DPC to evaluate IL-4, IL-8, IL-10,
IFN-, and TNF- cytokine secretion proﬁles by ELISA. Procedures
were performed as per the manufacturer’s instructions (Invitrogen,
Carlsbad, CA). Additionally, at necropsy (15 DPC), 106 tracheo-
bronchial lymph node (TBLN) mononuclear cells (MNCs) and lung
MNCs were restimulated with 200 TCID50 of the respective chal-
lenge PRRSV similar to that described in Ferrari et al. [12]. Cell
culture supernatants were analyzed by ELISA for IL-10 cytokine
secretion (Invitrogen).
2.6.  Flow cytometry analysis
Peripheral  blood mononuclear cells (PBMCs) were isolated from
heparinized blood samples by Ficoll–Hypaque gradient centrifu-
gation using Histopaque®-1077 (Sigma–Aldrich, St. Louis, MO).
Flow cytometry analysis was  performed to determine differ-
ent lymphocyte populations based on the cell surface marker
phenotype: T-helper cells (CD3+CD4+CD8−), cytotoxic T lym-
phocyte (CD3+CD4−CD8+), Th/memory cells (CD3+CD4+CD8+),
T-regulatory cells (CD4+FoxP3+CD25+) and  T cells (CD8+
TcR1N4+). The mouse anti-pig TcR1N4 antibody was  purchased
from VMRD (Pullman, WA), and all other antibodies were pur-
chased from BD Biosciences (San Jose, CA). Immuno-stained cells
were acquired using a FACS Caliber (BD Biosciences) ﬂow cytome-
ter. Frequencies of individual lymphocytes were analyzed by
100,000 events using FlowJo software (Tree Star, Inc., Ashland,
OR).
2.7. Statistical analysis
All  data were expressed as the mean value of ﬁve pigs ± SEM.
The differences in the level of humoral response, cytokine pro-
duction and viremia among each group were determined by the
one-way analysis of variance (ANOVA) followed by post hoc Tukey’s
test using Sigmaplot 11 software (Systat Software Inc., San Jose,
CA). Differences were considered statistically signiﬁcant when
p < 0.05.
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. Results
.1. H9e adjuvant enhances cross-protection efﬁcacy of MLV  to
eterologous  PRRSV infection in pigs
Our previous studies showed that H9e hydrogel can be a safe,
fﬁcacious adjuvant for the killed H1N1 swine inﬂuenza vac-
ines, resulting in signiﬁcantly higher hemagglutination inhibition
iters and antibody titers to swine inﬂuenza than immunization
ith antigen alone [10]. Since H9e acts as a potent adjuvant
or killed subunit vaccines, we hypothesized that H9e hydro-
els could also work as an adjuvant for a modiﬁed live PRRS
accine.
H9e solution is a free-ﬂowing solution at ambient tempera-
ure, and forms an injectable hydrogel at physiological conditions.
9e was easily mixed with MLV  and showed no virucidal effects
n the vaccine virus (data not shown). Pigs were vaccinated
ith Ingelvac PRRS MLV  vaccine alone (MLV), Ingelvac PRRS
LV vaccine adjuvanted with hydrogel H9e (MLV + H9e), or PBS
mock). Twenty-eight days post vaccination (DPV), pigs were sub-
ected to virus challenge with low virulence homologous VR-2332
1 × 106 TCID50/pig) or moderately virulent heterologous MN184A
5 × 105 TCID50/pig) strains of PRRSV. The mean body temperature
f unvaccinated pigs challenged with VR-2332 or MN184A was  0.3
r 1.0 ◦C higher than vaccinated pigs, respectively, with no differ-
nce between vaccinated groups (data not shown). Interestingly,
igs vaccinated with MLV  gained signiﬁcantly less weight than
nvaccinated and MLV  + H9e vaccinated pigs at 28 DPV (Fig. 1A and
), suggesting that the un-adjuvanted MLV  vaccine virus may cause
ub-clinical disease in pigs.
To determine if vaccinated pigs were protected from homol-
gous or heterologous virus challenge, titers of circulating virus
ere measured 7 days post challenge (DPC). We  found that the
igs vaccinated with MLV  + H9e were able to signiﬁcantly clear
oth the VR-2332 and MN184A strains circulating in the blood
 days post challenge (7 DPC). Pigs vaccinated with MLV  alone
ere able to signiﬁcantly clear the homologous VR-2332 virus
train (Fig. 1C). The pigs vaccinated with MLV  alone had reduced
iral load in the blood after MN184A challenge; however, it
as not statistically signiﬁcant from that in the unvaccinated-
hallenged group of pigs (Fig. 1D). Taken together, these results
uggest that the addition of H9e adjuvant to PRRSV MLV  vac-
ines can enhance protection against genetically distinct stains of
RRSV.
.2. Pigs vaccinated with MLV  + H9e have increased vaccine virus
irculation in the blood after vaccination
H9e rapidly forms a gel once it is formulated with MLV.
herefore, we suspect that the H9e nanoﬁber network may  act
s a scaffold to prolong vaccine virus entry into the blood or
nhance its replication within the host to enhance the vac-
ine’s protective effects. To determine if H9e adjuvant affects
he viral load of the vaccine strain of PRRSV in vaccinated pigs,
e measured circulating viral load in the serum of all pigs
eekly. Interestingly, pigs vaccinated with MLV  + H9e started to
evelop signiﬁcantly higher levels of circulating virus two  weeks
fter vaccination and reached an average maximum of 5.5-fold
9057 ± 402 TCID50 equivalent/ml) higher virus titers than that in
igs vaccinated with MLV  alone (1638 ± 625 TCID50 equivalent/ml)
n 21 DPV (Fig. 2A). By 28 DPV, the MLV  virus was  eliminated
rom the blood of pigs in all groups. Therefore, our results sug-
est that H9e may  act to stabilize the MLV  virus within the host
nd thus to increase the exposure of antigen to the host immune
ystem.2013) 4508– 4515
3.3. H9e–MLV vaccinated pigs show enhanced PRRSV-speciﬁc
antibodies and PRRSV neutralizing antibodies
To determine whether increased antigen exposure might lead
to enhanced humoral and cellular immune responses in vaccinated
pigs, we ﬁrst evaluated antibody responses of pigs vaccinated with
PRRSV MLV  in the presence or absence of H9e. Serum samples were
analyzed by commercial IDEXX PRRSV-speciﬁc antibody ELISA. By
14 DPV, 9 out of 10 pigs vaccinated with MLV  + H9e were pos-
itive for PRRSV-speciﬁc antibodies (as deﬁned by manufacturer
at S/P ratio ≥0.4), compared with only 5 out of 10 pigs in MLV
alone groups (Fig. 2B and Supplemental Fig. 1). Therefore, these
results suggest that addition of H9e adjuvant results in the ear-
lier onset of PRRSV antibodies than MLV  alone. By 21 DPV, all
vaccinated pigs had seroconverted to anti-PRRSV antibody posi-
tive.
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.vaccine.
2013.07.080.
PRRSV  MLV  vaccination is characterized by generation of early
non-protective antibodies speciﬁc to the nucleocapsid protein (as
measured by IDEXX ELISA) and delayed generation of protective
virus neutralizing antibodies. To determine if the H9e-mediated
prolonged viremia affects the production of neutralizing antibod-
ies as well, the PRRSV neutralizing antibody titers (VN titers) were
analyzed. On 28 DPV, pigs vaccinated with MLV  + H9e had similar
VN titers to both VR-2332 and MN184A as that in pigs vaccinated
with MLV-alone (Fig. 2C). After homologous VR-2332 viral chal-
lenge, pigs vaccinated with MLV  + H9e had signiﬁcantly higher VN
titer to VR-2332 and comparable VN titer to MN184A compared
with pigs vaccinated with MLV  alone (Fig. 2D). However, all vacci-
nated pigs developed similar levels of VN titers after heterologous
MN184A viral challenge (Fig. 2E). Therefore, our results show that
the addition of H9e hydrogel adjuvant can induce early on-set
and enhanced antibody production over vaccinating pigs with MLV
alone.
3.4. Pigs vaccinated with MLV  + H9e hydrogel have increased
pro-inﬂammatory cytokines and reduced immunosuppressive
cytokine secretion proﬁles
Because  we found that H9e can improve the humoral immune
responses of pigs to the PRRS MLV  vaccine, we  next assayed
the effects of H9e adjuvant on MLV-elicited cytokine proﬁles.
In doing so, sera at 7 DPC were analyzed for the presence of
IL-4, IL-8, IL-10, IFN- and TNF-. As shown in Fig. 3, the levels
of IFN-, but not TNF-, in the sera from MLV  + H9e vaccinated
pigs was  signiﬁcantly higher than that in pigs vaccinated with
MLV-alone after challenge (Fig. 3A and B). The levels of IL-4 and
IL-8 in sera from pigs vaccinated with MLV  + H9e were signiﬁ-
cantly higher than that from pigs vaccinated with MLV-alone when
the pigs were challenged with VR-2332 PRRSV (Fig. 3C and D).
Conversely, the secretion of immunosuppressive cytokine IL-10
in sera of MLV  + H9e vaccinated pigs was reduced compared with
that in the MLV-alone vaccinated pigs after challenge with both
VR-2332 and MN184A (Fig. 3E). IL-10 expression levels of lung
and TBLN MNCs also were analyzed at necropsy (15 DPC). As
shown in Fig. 3E, after these cells were re-stimulated with either
VR-2332 or MN184A in vitro, reduced IL-10 cytokine levels were
observed in the supernatant of lung and lymph node MNCs of
the pigs vaccinated with MLV  + H9e. Therefore, our results sug-
gest that addition of H9e to MLV  vaccine alters cytokine expression
proﬁles.
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Fig. 1. H9e adjuvant enhances protection efﬁcacy of MLV to homologous and heterologous PRRSV infection in pigs. Pigs (3-week-old) were vaccinated with MLV  or MVL  + H9e
and  challenged with the VR-2332 or MN184A strain of PRRSV 28 days post vaccination. (A and B) Fold body weight gain during the duration of the experiment was  determined.
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.5. Pigs vaccinated with MLV  + H9e display decreased
-regulatory and increased Th/memory lymphocyte
ubpopulations
To verify if the change in cytokine expression patterns was
ssociated with changes in lymphocytes population, the frequen-
ies of T-helper cells, cytotoxic T lymphocyte, Th/memory cells,
-regulatory cells and  T cells in blood, lung, and lymph nodes
ere evaluated using ﬂow cytometry analysis. As shown in Fig. 4,
 signiﬁcant decrease of the T-regulatory (Treg) lymphocyte pop-
lation (Fig. 4A) and increase of the Th/memory lymphocyte
opulation (Fig. 4B) was observed in the blood of pigs vaccinated
ith MLV  + H9e than that in pigs vaccinated with MLV  alone 4
eeks after vaccination. The decrease of Treg lymphocyte popula-
ion and increase of Th/memory lymphocyte population were also
bserved 14 DPC in pigs challenged with homologous VR-2332 or
eterologous MN184A PRRSV in blood, TBLN, and lung MNC  sam-
les (Fig. 4C and D). Additionally, we examined Th cells, CTL,  T
ells and NK cell population before and after challenge and found
o signiﬁcant changes in any groups (data not shown).
.  DiscussionCurrent commercial vaccines, both killed virus and modiﬁed
ive, are deﬁcient in protecting swine herds from the consistently
volving ﬁeld isolates of PRRSV [13]. One approach to improv-
ng PRRSV vaccine efﬁcacy is the addition of immunomodulatoryallenge (DPC) by RT-PCR. Viremia data are shown as mean ± SEM (n = 5). Bracketed
adjuvants including water–oil emulsions, aluminum, bacterial
components, and polymers to killed or live modiﬁed PRRSV
vaccines [14]. Interestingly, a new class of adjuvants, nanopar-
ticles, has been shown to increase the cross-protection efﬁcacy
of killed PRRSV vaccines. In a recent study by Dwivedi et al.,
PLGA nanoparticle-entrapped killed PRRSV vaccine induces a
cross-protective immune response against heterologous PRRSV
challenge via enhanced innate and PRRSV-speciﬁc adaptive
responses [15]. However, further studies are needed to reduce
the cost and complexity of nanoparticle production before
nanoparticle-based vaccines can be widely used as commercial
products. Some more cost-effect commercial water-in-oil emulsion
and polymers adjuvants, such as MontanideTM ISA 15A and Gel01
ST, have also been utilized in live modiﬁed PRRSV vaccines [6]. Dev-
ille et al. showed that pigs vaccinated with adjuvanted MLV  vaccine
containing 50% of the antigen load had equivalent protection as pigs
vaccinated with full dose of vaccine without the adjuvant.
We  recently reported that a biodegradable hydrogel could act as
an adjuvant for killed swine inﬂuenza vaccines [10]. These previous
results show that when H9e hydrogel was  used in place of the sup-
plied adjuvant of commercially available FluSure XP (Zoetis Inc.),
the H9e-adjuvanted vaccine led to signiﬁcantly higher HAI titers
and equivalent IgG antibody responses than the standard formula-
tion of FluSure. Based on these results, we  explored the ability of
H9e hydrogel to act as an adjuvant for PRRS modiﬁed live virus vac-
cine and here we  demonstrated that H9e hydrogels enhanced the
vaccine’s protective effects for both homologous and heterologous
PRRSV infection.
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H9e hydrogel forms a biodegradable nanoﬁber network under
hysiological conditions [16]. Peptide-based nanoﬁber networks
ave been shown to aid in the controlled release of growth factors,
herapeutics, and viruses [17–19]. Therefore, we hypothesized that
his nanoﬁber network could create pockets that the vaccine virus
ould occupy and thus act as an antigen depot such that PRRS virus
s presented slowly to the host immune system. We  show here that
he H9e had no virucidal effects and was able to facilitate increased
RRS vaccine virus presentation to the host, as shown by enhanced
accine virus circulation in the blood (Fig. 2A). These results suggest
igh vaccine virus titers in the blood induced by MLV  + H9e vacci-
ation may  facilitate the generation of an early and robust PRRSVimmune  response and provide better protection against genetically
diverse strains of PRRSV.
In  addition to high circulating vaccine virus, pigs vaccinated
with MLV  + H9e had earlier on-set of PRRS-speciﬁc ELISA antibod-
ies and enhanced neutralizing antibody titers to homologous virus.
Previous reports have shown that PRRSV-speciﬁc antibodies can
appear as soon as one week post-vaccination or challenge, how-
ever seroconversion is often observed between 14 and 21 days
post exposure [6,20]. Our results are consistent with these reports
and we  found that addition of H9e adjuvant reduced the time that
most pigs became positive for PRRSV-speciﬁc antibodies (Fig. 2B
and Supplemental Fig. 1).
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In order to gain insight into the immunologic mechanisms
mployed by the hydrogel adjuvant, cytokine expression levels
fter PRRSV challenge were compared among vaccinated groups
f pigs. We  found that the Th1-related cytokine IFN- in the
era of pigs vaccinated with MLV  + H9e was signiﬁcantly higher
han that of pigs vaccinated with MLV  alone after both homolo-
ous and heterologous challenges (Fig. 3A and B). IFN- is a key
ytokine that is associated with host cell-mediated immunity (CMI)
esponse, which is secreted by natural killer cells and several differ-
nt T cell subpopulations, and its expression is often decreased byith corresponding PRRSV strains. Bracketed groups were compared and * denotes
PRRSV infection [21,22]. These studies suggest that decreased IFN-
expression allows PRRSV to evade the host immune response and
result in chronic PRRS infections. Interestingly, a recent study using
two  different PRRSV strains reported that systemic enhancement
of IFN- further activates natural killers and T cell subpopulations
creating a positive feedback loop for the rapid clearance of PRRSV
[23].
Therefore, the elevated production of IFN- observed in the pigs
vaccinated with H9e + MLV  could explain the increased PRRS viral
clearance and improved protective immune response we observed.
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The expression of inﬂammatory cytokine IL-8, but not TNF-,
as increased in pigs vaccinated with H9e–MLV when pigs were
hallenged with homologous VR-2332 virus (Fig. 3B and D). In pre-
ious studies, low serum IL-8 levels are related to persistent PRRSV
nfection, and elevated IL-8 levels in serum is correlated with the
learance of PRRS virus [24,25]. Although our results also indicated
L-8 may  play a role in vaccination-induced clearance of PRRS virus,
urther experimentation is required to fully characterize the ability
f H9e adjuvant to modulate IL-8 expression levels.
The Th2-related cytokine IL-4 was increased in the sera of
igs vaccinated with MLV  + H9e compared with the pigs vacci-
ated with MLV  alone only after homologous VR-2332 challenge.
L-4 expression has been shown to control macrophage inﬂam-
atory activities in the pig [26]. While IL-4 expression levels
n PRRSV-infected pigs can remain unaltered [27], recent stud-
es suggest that natural PRRSV infection can signiﬁcantly induce
he expression of IL-4 [28], suggesting that PRRSV-mediated IL-4
nduction may  be strain dependent. In our hands, the increased IL-4
xpression after VR-2332 challenge correlated well with enhanced
rotection of pigs vaccinated with MLV  + H9e than that of pigs vac-
inated with MLV-alone. This indicates IL-4 may  play a positive role
n the immune response to PRRSV infection.PRRSV infection or vaccination has been shown to induce a
trong immunosuppressive response characterized by promoting
he secretion of IL-10 to antagonize the protective Th1 immune
esponse [29,30]. In our study, we found that the concentrationsV and (D) on 14 DPC. Data is shown as mean ± SEM (n = 5). Bracketed groups were
of  IL-10 in the serum and tissues of pigs vaccinated with MLV
alone were consistently higher than that from pigs vaccinated with
MLV  + H9e (Fig. 3E). IL-10 is mainly produced by a small subpopu-
lation of T lymphocytes termed T-regulatory cells [31]. Consistent
with IL-10 levels, the frequency of T regulatory cells in MLV + H9e
vaccinated pigs was  dramatically reduced in blood, lung MNCs,
and TBLNs post infection (Fig. 4C). Therefore, it is likely that the
reduced T-regulatory cell population and production of IL-10 may
contribute to the enhanced Th1 response and efﬁcient elimination
of PRRSV after challenge in the pigs vaccinated with MLV  + H9e.
CD4+CD8+ T cells, which include T-helper, cytolytic, and mem-
ory properties, are a major type I IFN- cytokine secreting
population [32]. In our study, pigs vaccinated with MLV + H9e gen-
erated signiﬁcantly higher Th/memory cell populations both before
and after challenge compared to the unvaccinated and MLV  vac-
cinated pigs. This result is consistent with the observation that
IFN- production is elevated in pigs vaccinated with MLV  + H9e.
The high frequency of functional T memory cells may contribute to
rapid recall response for the quick elimination of subsequent PRRS
virus exposure [33]. The ability of H9e adjuvant to shift MLV  vac-
cine from mainly humoral, to a response having both humoral and
cell-mediated immune responses suggest that CMI may  be impor-
tant for increased vaccine protection potential. Our results support
the notion that MLV  + H9e may  act to enhance IFN- and reduce
IL-10 production via increasing Th/memory and decreasing Treg
lymphocyte populations, thereby causing a shift to a Th1-type
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mmune response to provide a better protection against PRRSV
nfection.
We have previously shown that ﬂexible polymer adjuvants such
ontanideTM Gel01 ST also can enhance the protective effects of
odiﬁed live PRRSV vaccines: however, their enhanced protective
ffects are limited to homologous re-infection [11]. Interestingly, it
as demonstrated that the addition of Gel01 adjuvant to MLV  vac-
ine could enhance vaccine-induced antibody-mediated immunity
ut did not promote a stronger cellular-mediated immunity. Fur-
hermore, Gel01 adjuvanted MLV  did not show improved efﬁcacy
n reducing heterologous challenge-induced viremia as compared
ith MLV  alone. Thus, these results and our previous work suggest
hat the vaccine’s ability to generate a cellular-mediated immune
esponse may  be essential to mediate its cross-protective efﬁcacy
gainst PRRSV infection.
.  Conclusion
This study shows that H9e hydrogel as an adjuvant for MLV
an improve vaccination-induced host protection against RRRSV
nfection by increased circulation of the vaccine virus in the blood,
nhanced antibody production, and increased CMI  responses. We
elieve that the addition of H9e hydrogel adjuvant to existing vac-
ines is an exciting method to improve PRRS live vaccine efﬁcacy.
hese results encourage us to explore the ability of H9e to work as
 universal adjuvant for a broad range of animal vaccines.
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